RxDoctor Payments Data

Charles Lawler, MD

Internal Medicine · Chicago, ILNPI 1356324867

Payments from drug & device makers

$966in general payments, 2019–2025

Across 71 payments — averaging $13.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$309
  • Novo Nordisk$254
  • Lilly USA, LLC$125
  • AstraZeneca$92
  • Amgen$50
  • Johnson & Johnson$36
  • plus $100 from 4 others

What the payments were for

  • Food & beverage$95399%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$966 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$189,705
Medicare patients
347
Services billed
1,908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin146$212,350
EliquisApixaban87$100,308
XareltoRivaroxaban25$33,412
JanuviaSitagliptin Phosphate24$32,170
OzempicSemaglutide20$31,258
FarxigaDapagliflozin Propanediol21$25,142
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,629
TrulicityDulaglutide11$14,006
Breo ElliptaFluticasone/Vilanterol11$7,147
Atorvastatin Calcium502$4,495
Incruse ElliptaUmeclidinium Bromide12$4,271
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$4,173
Metoprolol Succinate256$3,923
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$3,835
Rosuvastatin Calcium250$3,497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$309$100,30887 claims
Johnson & JohnsonXarelto$36$33,41225 claims
Novo NordiskOzempic$254$31,25820 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$34$26,04740 claims
AstraZenecaFarxiga$92$25,14221 claims
Lilly USA, LLCTrulicity$125$14,00611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →